134 related articles for article (PubMed ID: 37700448)
1. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
[TBL] [Abstract][Full Text] [Related]
2. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
Brown NF; Carter T; Mulholland P
CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
[TBL] [Abstract][Full Text] [Related]
5. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
6. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
10. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
13. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
14. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
Purkait S; Bansal S; Malgulwar PB
Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
[TBL] [Abstract][Full Text] [Related]
16. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
Kim SH; Hwang K; Lee KS; Choe G; Kim CY
World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
[TBL] [Abstract][Full Text] [Related]
17. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
[TBL] [Abstract][Full Text] [Related]
18. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
19. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
20. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
